Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
11.57
Nov 13 • 3:59 PM ET Dollar change-0.33 Percentage change(-2.77%)
Aftermarket Close
11.45
Aftermarket • 7:30 PM ET Dollar change-0.12 Percentage change(-1.04%)
Index
RUT
Market Cap
1.76B
Enterprise Value
1.85B
Income
-7.60M
Sales
398.74M
Book/sh
6.41
Cash/sh
1.41
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
1576
IPO
Dec 11, 2020
P/E
-
Forward P/E
29.23
PEG
23.01
P/S
4.43
P/B
1.80
P/C
8.21
P/FCF
22.57
EV/EBITDA
20.91
EV/Sales
4.64
Quick Ratio
2.58
Current Ratio
2.58
Debt/Eq
0.31
LT Debt/Eq
0.30
Option/Short
Yes / Yes
EPS (ttm)
-0.05
EPS next Y
0.40
EPS next Q
0.10
EPS this Y
-24.02%
EPS next Y
18.42%
EPS next 5Y
1.27%
EPS past 3/5Y
- 50.19%
Sales past 3/5Y
7.66% 11.45%
EPS Y/Y TTM
-169.67%
Sales Y/Y TTM
-4.05%
EPS Q/Q
-317.89%
Sales Q/Q
-9.29%
Insider Own
36.33%
Insider Trans
0.00%
Inst Own
74.82%
Inst Trans
-4.58%
ROA
-1.65%
ROE
-2.38%
ROIC
-0.60%
Gross Margin
49.87%
Oper. Margin
4.44%
Profit Margin
-1.91%
SMA20
4.45%
SMA50
19.30%
SMA200
57.06%
Trades
Shs Outstand
152.54M
Shs Float
97.13M
52W High
12.61 -8.25%
52W Low
4.45 160.00%
Volatility
5.26% 5.81%
ATR (14)
0.60
RSI (14)
60.00
Beta
1.25
Rel Volume
1.00
Avg Volume
2.67M
Volume
2,672,879
Perf Week
-3.98%
Perf Month
19.77%
Perf Quarter
44.62%
Perf Half Y
158.26%
Perf YTD
31.33%
Perf Year
37.57%
Perf 3Y
-11.14%
Perf 5Y
-70.30%
Perf 10Y
-
Prev Close
11.90
Price
11.57
Change %
-2.77%
Consensus
Buy
Avg. Price Target
$12.68
Implied Upside
+9.6%
Analysts14incl. previous ratings
Rating Distribution6 Buy · 8 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Mar 06, 2026Downgrade
BCS logoBBarclays
Overweight → Equal Weight$8-30.9%
Feb 27, 2026Downgrade
CCraig Hallum
Buy → Hold$10-13.6%
Jan 06, 2026Upgrade
LLeerink Partners
Market Perform → Outperform$13+12.4%
Nov 21, 2025Initiated
RRothschild & Co Redburn
Buy$10-13.6%
Nov 13, 2025Initiated
BMO logoBBMO Capital Markets
Market Perform$9-22.2%
Sep 29, 2025Initiated
CCraig Hallum
Buy$16+38.3%
Jul 03, 2025Resumed
MS logoMMorgan Stanley
Equal-Weight$16+38.3%
May 08, 2025Upgrade
BCS logoBBarclays
Equal Weight → Overweight$14+21.0%
Feb 27, 2025Initiated
TD logoTTD Cowen
Buy$16+38.3%
Sep 27, 2024Upgrade
UBS logoUUBS
Neutral → Buy$16+38.3%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pedersen Leif EOfficerSep 03 '26Proposed Sale8.3236,066300,069Sep 03 11:09 AM
Anhalt RonaChief Human Resources OfficerJun 01 '26Option Exercise0.007,147019,030Jun 02 05:15 PM
Corcoran DanielSVP and General CounselJun 01 '26Option Exercise0.0022,830039,939Jun 02 05:14 PM
Collins CynthiaDirectorMay 14 '26Option Exercise0.0015,757051,846May 15 04:31 PM
Reynders John V WChief Financial OfficerMay 14 '26Option Exercise0.0015,757026,466May 15 04:29 PM
BROSHY ERANChairmanMay 14 '26Option Exercise0.0015,757050,708May 15 04:28 PM
Bedi ArjunDirectorMay 14 '26Option Exercise0.005,54705,547May 15 04:28 PM
CASHMAN JAMES E IIIChairmanMay 14 '26Option Exercise0.0015,7570484,197May 15 04:27 PM
Killefer NancyDirectorMay 14 '26Option Exercise0.0015,757051,846May 15 04:26 PM
Crane Rosemary ADirectorMay 14 '26Option Exercise0.0015,757045,672May 15 04:26 PM
WALSH MATTHEW MDirectorMay 14 '26Option Exercise0.0015,7570213,316May 15 04:25 PM
Resnick Jon MatthewChief Executive OfficerMay 11 '26Option Exercise0.0059,766059,766May 13 04:53 PM
Pedersen Leif EPRESIDENT, CHIEF COMMERCAL OFFApr 01 '26Option Exercise0.0033,1670113,744Apr 03 04:11 PM
McKemey AdrianPresident, Drug Dev. SolutionsApr 01 '26Option Exercise0.0010,849010,849Apr 03 04:10 PM
Corcoran DanielSVP and General CounselApr 01 '26Option Exercise0.0010,849027,070Apr 03 04:09 PM
Gallagher John EChief Financial OfficerApr 01 '26Option Exercise0.0050,6050103,174Apr 03 04:07 PM
Aspbury RobertPRESIDENT, PREDICTIVE TECHApr 01 '26Option Exercise0.0033,1670339,581Apr 03 04:06 PM
Anhalt RonaChief Human Resources OfficerApr 01 '26Option Exercise0.009,764014,945Apr 03 04:04 PM
Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017 and is headquartered in Radnor, PA.
Senior AdvisorMr. Leif E. Pedersen
CEO & DirectorMr. Jon Resnick
President & Chief Commercial OfficerMr. Julien Perrier
Interim CFOMr. Faiz Mohammed
Chief Technology Officer & Chief AI OfficerDr. Christopher Bouton Ph.D.